Please login to the form below

Not currently logged in
Email:
Password:

Bicycle Therapeutics appoints Lee Kalowski

He joins the biotech from Tokai Pharmaceuticals

Lee KalowskiBiotechnology group Bicycle Therapeutics has appointed Lee Kalowski as chief financial officer at a time when the company explores a new class of therapeutics based on its proprietary bicyclic peptide product platform.

Prior to joining Bicycle, Kalowski served as the chief financial officer of Tokia Pharmaceuticals, where he helped lead the company’s $105m initial public offering in 2014.

He said: “Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively.

“I am trilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech.”

Kalowski has also served Credit Suisse as its vice president, global biotechnology equity research and he has also worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson.

Kevin Lee, chief executive officer of Bicycle Therapeutics, said: “We are delighted to welcome Lee to the Bicycle team at this exciting time for our company.

“He brings a wealh of experience working with biotech companies at all stages of their evolution, both as a wall street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”

9th August 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics